Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Cataract surgery combined with canaloplasty

Poster Details

First Author: M.Genidy EGYPT

Co Author(s):    H. Zein                    

Abstract Details

Purpose:

To demonstrate that at 2 years Phaco-canaloplasty is a safe and efficacious procedure in terms of IOP reduction and visual improvement in Primary open-angle glaucoma patients with cataracts.

Setting:

Department of Ophthalmology,Minia Universit Hospital, Faculty of Medicine, Minia, Egypt

Methods:

Non randomised prospective trial over a period of 2 years, 60 eyes of 50 patients with primary open-angle glaucoma were selected for phaco canaloplasty and operated based on the following criteria. Visually significant cataracts with IOP over 25 mmHg on maximally tolerated medication or intolerance to or non compliance with IOP over 25mmHG. Phaco Canaloplasty with foldable IOL implantation was carried out with a fibreoptic canaloplasty device. IOP was measured with applanation tonometry at day 7, one month, 3 months, 6 months and 9 months. Vision was recorded on day 7, one month, 3 months, 6 months and one year.

Results:

Day 7 IOP was between 4-8. One month, 9-14. 3 months, 12-15. 6 months, 14-17. One year, 14-18 mmHg. By 1 year 12 eyes of 9 patients were lost to follow-up. 30 eyes had pressures between 14 and 18 without any meds.18 eyes controlled with one medication. Best corrected vision was 6/6-6/9 in 22of 60 eyes at 7 days. One month, 30 out of 60 eyes were between 6/9 - 6/6. By one year it was 26 of 48 eyes between 6/9 and 6/6 as some eyes were lost to follow-up.

Conclusions:

Phaco- Canaloplasty is efficacious and safe in glaucoma patients with cataracts by decreasing IOP and increasing vision.

Financial Disclosure:

NONE

Back to Poster listing